Judith Greciet, invited as guest speaker at international Allicense Conference May 5-6, 2015 – San Francisco, CA

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Judith Greciet, CEO of Onxeo, has been invited to participate to the 2015 Allicense Conference as a panelist for the session entitled “Eat or Be Eaten—The Specialty Pharma Survival Story”.

As one of the active deal-making organizations during the last months, especially with the last year’s acquisition and merger of TopoTarget by BioAlliance Pharma, Onxeo is a particularly compelling story, and certainly unique among mid-size European-based biotechs. Judith Greciet will contribute as a player and a witness to this very timely topic, with the recent Onxeo’s story of increasing size and critical mass through a merger in order to emerge as new global playor in the orphan oncology drugs area.

Allicense Conference brings together professionals from the Pharma, Biotech and Financial communities. It offers opportunities for exchange of information and debate, especially in dealmaking, licensing and business development areas.

The conference takes place on May 5 and 6 (the session “Eat or Be Eaten—The Specialty Pharma Survival Story” is on the 6th at 2:15pm) at the Park Central Hotel in San Francisco.